valsartan has been researched along with Dyslipidemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gegeshidze, N; Kapetivadze, V; Lazashvili, T; Maglapheridze, Z; Tabukashvili, R; Tchaava, K | 1 |
| Abdillah, A; Kalim, H; Setiawati, A | 1 |
| Akhtari, S; Andalib, A; Curnew, G; Leclerc, JM; Rigal, R; Tardif, JC; Vaillancourt, M | 1 |
| Akhan, M; Arslan, E; Arslan, Z; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Saglam, K; Sarlak, H | 1 |
1 trial(s) available for valsartan and Dyslipidemia
| Article | Year |
|---|---|
An additional LDL-lowering effect of amlodipine; not only an antihypertensive?
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Essential Hypertension; Female; Humans; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Tetrazoles; Triglycerides; Valine; Valsartan | 2013 |
3 other study(ies) available for valsartan and Dyslipidemia
| Article | Year |
|---|---|
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hypertension; Hypolipidemic Agents; Middle Aged; Valsartan | 2018 |
Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Drug Combinations; Drug Substitution; Dyslipidemias; Edema; Female; Headache; Humans; Hypertension; Indonesia; Male; Medication Adherence; Middle Aged; Prospective Studies; Valsartan | 2015 |
Determinants of masked hypertension in hypertensive patients treated in a primary care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Comorbidity; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Masked Hypertension; Middle Aged; Obesity; Prevalence; Primary Health Care; Quebec; Risk; Tetrazoles; Valine; Valsartan; White Coat Hypertension | 2012 |